Abbott Laboratories (ABT) vs Novo Nordisk A/S (NVO)
A side-by-side comparison of Abbott Laboratories and Novo Nordisk A/S across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of September 13, 2026. Differences are shown without an overall score or investment verdict.
ABT
Abbott Laboratories
$102.04HealthcareDelayed quote: Sep 15, 2026, 10:30 AM EDT
NVO
Novo Nordisk A/S
$42.60HealthcareDelayed quote: Sep 15, 2026, 10:30 AM EDT
Total return — ABT vs NVO
growth of $100 · dividends reinvested · last 10yABT +193.7% (+11.4%/yr)NVO +135.8% (+9.0%/yr)ABT compounded faster over this window
ABT NVO
ABT vs NVO: by the numbers
- •NVO is the larger company ($189.15B vs $176.57B market cap).
- •NVO trades at the lower trailing earnings multiple (10.50 vs 32.81 P/E), one valuation lens rather than an overall verdict.
- •NVO converts more revenue to profit (35.33% vs 11.65% net margin).
- •NVO grew revenue faster over the past five years (19.76% vs 2.98% CAGR).
- •NVO pays the higher dividend yield (4.17% vs 2.43%).
Metrics side by side
Valuation
| Metric | ABT | NVO |
|---|---|---|
| P/E ratio | 32.81 | 10.50 |
| Forward P/E | 18.50 | N/A |
| P/S ratio | 3.79 | 3.70 |
| P/B ratio | 3.45 | 5.61 |
| EV / EBITDA | 18.74 | 7.77 |
| FCF yield | 4.49% | 3.94% |
Profitability
| Metric | ABT | NVO |
|---|---|---|
| Gross margin | 56.80% | 80.64% |
| Operating margin | 17.03% | 43.10% |
| Net margin | 11.65% | 35.33% |
| ROE | 10.61% | 53.50% |
| ROIC | 6.07% | 30.21% |
Dividends
| Metric | ABT | NVO |
|---|---|---|
| Dividend yield | 2.43% | 4.17% |
| Payout ratio | 79.74% | 44.27% |
Growth (annualized)
| Metric | ABT | NVO |
|---|---|---|
| Revenue CAGR (5Y) | 2.98% | 19.76% |
| EPS CAGR (5Y) | 8.22% | 19.59% |
| FCF CAGR (5Y) | 0.18% | -1.45% |
| Total return CAGR (5Y) | -2.69% | -0.65% |
Frequently asked
- Which has the lower trailing P/E, ABT or NVO?
- NVO has the lower trailing P/E: ABT trades at 32.81 and NVO at 10.50. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, ABT or NVO?
- Over the past five years, NVO grew revenue faster — ABT at a 2.98% CAGR versus NVO at 19.76%.
- Does ABT or NVO pay a bigger dividend?
- ABT yields 2.43% and NVO yields 4.17% based on trailing dividends and the latest price.
- Is ABT or NVO more profitable?
- NVO runs the higher net margin — ABT at 11.65% versus NVO at 35.33%.
- How have ABT and NVO total returns compared?
- Over the past 10 years, ABT delivered 11.61% and NVO delivered 9.46% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Abbott Laboratories P/E ratioNovo Nordisk A/S P/E ratioAbbott Laboratories dividend yieldNovo Nordisk A/S dividend yieldAbbott Laboratories ROENovo Nordisk A/S ROEAbbott Laboratories operating marginNovo Nordisk A/S operating marginAbbott Laboratories revenue growthNovo Nordisk A/S revenue growthAbbott Laboratories free cash flowNovo Nordisk A/S free cash flow
Abbott Laboratories & Novo Nordisk A/S appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified September 13, 2026.